Want to see CH:ALC full AI Analyst Report?
ALC Stock Chart & Stats
CHF55.74
-CHF0.06(-0.11%)
At close: 4:00 PM EDT
CHF55.74
-CHF0.06(-0.11%)
Day’s Range― - ―
52-Week RangeCHF47.80 - CHF72.88
Previous CloseN/A
Volume1.70M
Average Volume (3M)1.46M
Market Cap
CHF27.67B
Enterprise ValueCHF31.95K
Total Cash (Recent Filing)CHF1.66B
Total Debt (Recent Filing)CHF5.25B
Price to Earnings (P/E)41.5
Beta1.05
Next Earnings
Aug 10, 2026EPS Estimate
0.61Next Dividend Ex-DateN/A
Dividend Yield0.51%
Share Statistics
EPS (TTM)1.65
Shares Outstanding499,700,000
10 Day Avg. Volume1,240,075
30 Day Avg. Volume1,456,701
Financial Highlights & Ratios
PEG Ratio39.53
Price to Book (P/B)1.79
Price to Sales (P/S)3.61
P/FCF Ratio21.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF71.13Price Target Upside27.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)2.76
Revenue Forecast (FY)CHF8.84B
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetConsistently low leverage and a sizable equity base give Alcon durable financial flexibility. This supports continued R&D, capital equipment investment and the $1.5B repurchase program without forcing asset sales or aggressive deleveraging, sustaining long-term strategic optionality.
Installed-base And Equipment MomentumStrong equipment placement increases the installed base, creating recurring consumable demand tied to procedure volumes. Durable equipment adoption (Unity platform) supports multi-year consumable revenue streams and higher lifetime customer value, insulating revenue versus short-term volume swings.
Product Innovation And Share GainsRapid uptake and high refill rates for Tryptyr plus broader IOL product gains indicate successful commercial execution and reimbursement traction. Durable product-led share gains expand addressable markets, deepen provider relationships and create recurring revenue as coverage and refill behavior scale.
Bears Say
Recent Earnings And FCF WeaknessA noticeable TTM decline in net income and margins reduces internal cash generation and raises risk to reinvestment and shareholder returns. If not reversed, weaker profitability can constrain R&D and capital placement cadence that drive long-term consumable and equipment growth.
Tariff-driven Margin PressureSustained tariff exposure materially compresses gross margins and introduces cost volatility. Even with a lower assumed tariff rate, recurring import duties can erode pricing power or force higher product prices, weakening competitive positioning and long-term margin sustainability.
China Weakness And Competitive HeadwindsSlower growth and heightened competition in China limit a key geographic growth engine for implantables and IOLs. Prolonged underperformance in China or share loss abroad reduces scale benefits and undermines global revenue diversification tied to higher-margin surgical products.
Alcon News
ALC FAQ
What was Alcon’s price range in the past 12 months?
Alcon lowest stock price was CHF47.80 and its highest was CHF72.88 in the past 12 months.
What is Alcon’s market cap?
Alcon’s market cap is CHF27.67B.
When is Alcon’s upcoming earnings report date?
Alcon’s upcoming earnings report date is Aug 10, 2026 which is in 4 days.
How were Alcon’s earnings last quarter?
Alcon released its earnings results on May 05, 2026. The company reported CHF0.662 earnings per share for the quarter, beating the consensus estimate of CHF0.636 by CHF0.026.
Is Alcon overvalued?
According to Wall Street analysts Alcon’s price is currently Undervalued.
Does Alcon pay dividends?
Alcon pays a Annually dividend of CHF0.28 which represents an annual dividend yield of 0.51%. See more information on Alcon dividends here
What is Alcon’s EPS estimate?
Alcon’s EPS estimate is 0.61.
How many shares outstanding does Alcon have?
Alcon has 499,700,000 shares outstanding.
What happened to Alcon’s price movement after its last earnings report?
Alcon reported an EPS of CHF0.662 in its last earnings report, beating expectations of CHF0.636. Following the earnings report the stock price went down -10.958%.
Which hedge fund is a major shareholder of Alcon?
Currently, no hedge funds are holding shares in CH:ALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alcon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF71.13 (27.61% Upside)
CHF71.13 (27.61% Upside)
Blogger Sentiment
Bullish
CH:ALC Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.74%
12-Months-Change
Fundamentals
Return on Equity
0.51%
Trailing 12-Months
Asset Growth
1.97%
Trailing 12-Months
Company Description
Alcon
Alcon Inc. is a global eye care enterprise dedicated to the research, development, manufacturing, and distribution of a comprehensive range of vision products for both eye care professionals and their patients worldwide. The company operates through two primary divisions. Its Surgical segment equips ophthalmic surgeons with advanced solutions for various procedures. This includes specialized equipment, diagnostic instrumentation, and implantable devices such as intraocular lenses (IOLs), alongside a full suite of consumables like viscoelastic substances, surgical solutions, and customized procedure kits. For cataract interventions, key offerings feature the Centurion Vision System, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA System for intra-operative measurements. Vitreoretinal surgeons benefit from systems like Constellation Vision, procedure packs, lasers, and a variety of specialized micro-instruments, including grieshaber and MIVS tools, scissors, forceps, medical-grade vitreous tamponades, and Hypervit vitrectomy probes. Refractive surgery innovations include WaveLight lasers and Contoura Vision for LASIK treatments, and the segment also provides the EX-PRESS glaucoma filtration device. Its IOL portfolio, prominently featuring AcrySof IQ, includes advanced technology lenses like PanOptix and ReSTOR, designed to correct presbyopia and astigmatism during cataract removal. The Vision Care segment addresses everyday eye health needs. It offers a diverse selection of contact lenses, including daily disposables, reusable options, and color-enhancing varieties. This segment also provides ocular health products for conditions such as dry eye, glaucoma, and allergies, in addition to contact lens care solutions, ocular vitamins, and redness-relieving drops. Prominent brands within this segment include TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux. Founded in 1945, the company was initially known as Alcon Universal S.A. before rebranding as Alcon Inc. in December 2001. Its headquarters are located in Geneva, Switzerland.
ALC Company Deck
ALC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely constructive picture: solid top-line growth across surgical, vision care and ocular health, strong early adoption and share gains from new product launches (Unity, PanOptix Pro, Tryptyr, Total30), a meaningful equipment acceleration and a shareholder-friendly $1.5B repurchase plan. Offsetting this optimism were market headwinds (soft cataract volumes, China weakness), tariff-driven margin pressure, modest operational disruptions (Hydrus supply, Middle East shipping) and near-term margin timing (Q2 SG&A peak). Management maintained full-year guidance (5%–7% sales growth; 70–170 bps core operating margin expansion) and positioned the back half of 2026 for stronger contribution from new products, implying overall confidence in durable growth despite short-term noise.View all CH:ALC earnings summariesALC Stock 12 Month Forecast
Average Price Target
CHF71.13
▲(27.61% Upside)